Drugs / NY-ESO-1 recombinant protein
NY-ESO-1 recombinant protein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02015416 | Nov 2013 → Dec 2016 | breast cancer, melanoma, non-small cell lung carcinoma, ovarian cancer +1 | Immune Design | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 recombinant protein | “NY-ESO-1 recombinant protein together with GLA-SE” NCT02015416 ↗ |
| Modality | Protein / enzyme biologic | “NY-ESO-1 recombinant protein together with GLA-SE” NCT02015416 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT02015416 ↗ |